Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
Authors' conclusion
Following a modified treat-to-target strategy, rates of CDAI remission/LDA and DAS28(CRP) <2.6/≤3.2 at 48 weeks were similar, regardless of starting therapy. However, patients initially receiving upadacitinib reached treatment targets more quickly and spent more time in clinical targets over the initial 48 weeks of treatment.
Study context
- Population
- Patients with RA and inadequate MTX response in SELECT-COMPARE
- Participants
- 651 vs 327
- Comparison
- Initial upadacitinib vs initial adalimumab after inadequate MTX response
- Upadacitinibn = 651
- Adalimumabn = 327reference
- Primary endpoint
- Achievement of treatment goals (clinical remission/low disease activity (LDA), physical function, pain, combined deep-response endpoint) and time-averaged response rates
- Follow-up
- 48 weeks
Methodological detailsblinded switch (modified treat-to-target), analysed by initial randomized group regardless of switch
- Blinded switch (modified treat-to-target)
- Analysed by initial randomized group regardless of switch
Primary result
As reported in the abstract
Treatment endpoints at week 48
Median time to DAS28(CRP) <2.6/≤3.2 earlier with initial upadacitinib
6-8 weeks
Original publication
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford). Published 26 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →